top of page



Board of Directors


Alan Au 

Board Observer

Alan has over 20 years of experience across healthcare investment banking, private equity and venture capital investments in Asia/China. He is Managing Partner at GT Healthcare Capital Group, a private equity fund focusing on cross border healthcare investments founded in 2015. Alan currently serves as a Board member and Audit Committee Chairman of CSPC Pharmaceutical Group (, a Hang Seng Index constituent company); he is also a Board member of I-Mab Biopharma Group (Nasdaq: IMAB), a clinical-stage biopharma. Besides, Alan serves as a panel member of the Innovation and Technology Fund of the Hong Kong SAR Government. Alan was a senior adviser to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in Dec 2013, when Alan was Chairman of the Special Committee on the Board of Directors). Alan has been the head of Investment Banking, M&A, Investment director, and managing partner at multiple firms responsible for healthcare investments in Asia. Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and a member of the American Institute of Certified Public Accountants. Alan received his Bachelor’s degree in Psychology from the Chinese University of Hong Kong and a Master’s degree in Management from Columbia Business School in New York.


John Cammett 


Co-Founder Realterm Private Equity

Mr. Cammett, a lifelong entrepreneur, is the co-founder of Realterm Private Equity Fund, which now represents over $5BN in assets through five logistics-oriented equity fund series.  John now sits on the Executive Management Committee of Realterm and the Investment Committees of the Funds.

Mr. Cammett has extensive experience investing in the Life Science sector. John is the major shareholder and a board member of several MedTech & Biotech companies.  John graduated from Harvard with an AB in Engineering and Applied Sciences.


Payson Coleman, Esq  


Senior Counsel, Pillsbury

Payson is highly experienced with privately held companies, private equity and non-profits.  He offers extensive legal and investment expertise as well as broad experience and critical thinking outside of the medical device and healthcare industries to compliment the other GI Windows board members.


V. Kadir Kadhiresan, PhD 


Vice President, Venture Investments

Johnson & Johnson Innovations

Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP).


Frederic Moll, MD  

Board Observer

Chief Development Officer, Johnson & Johnson Healthcare 

Dr Moll brings both clinical and business expertise to augment and compliment the GI Windows board.   He is globally recognized as the Founder of Robotics in healthcare.  Prior to J&J, Dr. Moll co-founded Auris Health (acquired by J&J, $5.7B) and served as Chief Executive Officer. Earlier in his career, Dr. Moll has founded and led several Medtech companies including co-founder of Intuitive Surgical Inc. (Stock ISRG), serving as its first Chief Executive Officer. 


Peter Rogal    

Board Observer

CEO, Gold Circuit Electronics Global Sales and Services LLC

Peter has over 40 years of experience in the high tech electronics industry and as a serial entrepreneur and business executive.  He has invested and maintains board seats in several rapidly growing Life Science companies.  He is the founder and 100% shareholder of Brooktrout Ventures, a small to midsized angel investing firm.

Dan Sheehan.jpg

Daniel T. Sheehan


Vice President of Venture Capital, Medtronic

Dan manages the activities of Medtronic Ventures, Medtronic’s Corporate Venture Capital investment group.  He began Corporate Venture investing in 2008, and since that time his teams have made investments in over 50 healthcare and medical technology companies.  Dan has served on several portfolio company boards and is passionate about working with managers and investors in emerging companies.  Prior to Medtronic, he was a General Partner with Affinity Capital Management, a healthcare-oriented venture capital firm. He has also managed the business development and strategic marketing efforts for Steris Corporation. He is a graduate of Fordham University and Columbia Business School

Screen Shot 2022-01-25 at 2.00.03 PM.png

Christopher Thompson, MD     


Director of Endoscopy, Brigham & Women’s Hospital

Professor of Medicine, Harvard Medical School

Dr. Thompson is the co-founder of Beacon Endoscopic and GI Windows.  He is one of the seminal international thought leaders in the rapidly emerging new fields of Natural Orifice Transluminal Endoscopic Surgery (NOTES) and Bariatric Endoscopy.  


Dr. Thompson received his MD degree from Pennsylvania State University College of Medicine and completed advanced Clinical and Research fellowships at Harvard Medical School.

bottom of page